Ease of administration and dual protection can drive novel intranasal vaccine adoption: GlobalData Read more
Disappointing SOLIDARITY results for remdesivir likely due to trial differences and not the drug: GlobalData Read more
Antibodies against SARS-CoV-2 wane over time, suggesting immunity may be short-lived: GlobalData Read more
Second wave of COVID-19 vaccines may not be needed to reach higher efficacy bar than first batch Read more
India’s role in global supply of COVID-19 drugs and vaccines remains crucial despite IPR waiver decision: GlobalData Read more